Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70 PLN | -0.85% | +2.94% | +19.66% |
03-28 | Selvita S.A. agreed to acquire PozLab sp. z o.o. | CI |
03-27 | Selvita S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 3.75 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.66% | 323M | - | ||
+22.85% | 47.9B | B- | ||
+46.56% | 41.42B | A | ||
-1.96% | 40.7B | B | ||
-6.20% | 28.92B | C | ||
+11.26% | 25.55B | B- | ||
-21.11% | 19.27B | B | ||
-1.32% | 12.15B | B+ | ||
+30.55% | 12.14B | C+ | ||
-0.72% | 11.99B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SLV Stock
- Ratings Selvita S.A.